Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation discusses the impact of H. pylori on nutrient absorption, specifically iron and B12. It also mentions checking serum DHT levels as a potential solution.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A 22-year-old male has been using finasteride for 4 months without major side effects but is concerned about hormone test results showing low SHBG and high estrogen. He plans to consult a doctor and is considering alternatives like minoxidil or topical finasteride to avoid health issues.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

OP used HIMS hybrid tablets containing 1.1mg finasteride, 3mg minoxidil, and 2.5mg biotin, showing significant hair regrowth after initial shedding. OP experienced no side effects and plans to continue treatment.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

The conversation is about a user sharing their positive progress with hair regrowth using oral minoxidil, biotin, finasteride, and other supplements. The user also mentions using a HIMS oral fin/min combo and receives advice and encouragement from others.

The conversation is about a user sharing their positive experience with Scalp Micropigmentation (SMP) for hair loss, highlighting the natural look achieved by a specialized artist. The procedure cost $2600 and was done by Alex Corona in Panama City Beach, FL.

Sebaceous filaments or blackheads on the scalp are not a cause of hair loss; it's more likely due to hormonal factors, particularly in androgen-sensitive areas like the temples and crown. The user is using topical finasteride, minoxidil, and tretinoin for treatment.

A 30-year-old man shared his 9-year experience with hair loss treatments, including finasteride, minoxidil, and dutasteride, noting that while the medications were effective, they caused side effects like lower libido, gynecomastia, and mental health issues. He decided to stop all medications due to concerns about mood, fertility, and overall happiness.

The conversation discusses a user's impressive hair regrowth progress over 17 months using a topical minoxidil and finasteride spray from HIMS, with suggestions to add microneedling for better results. Some users express skepticism about the authenticity of the results, while others inquire about side effects and application methods.

A 35-year-old man underwent a 6400 graft DHI hair transplant in Turkey, combined with scalp micropigmentation (SMP), to address severe hair loss from Norwood 7. He uses finasteride, oral and topical minoxidil, and GHK-CU, and is satisfied with the results, noting improved hair coverage and confidence despite some remaining thin areas.

Green tea extract and soy isoflavones may help with hair loss by inhibiting DHT and providing additional health benefits. Combining these with finasteride and possibly using nizoral shampoo could enhance effectiveness in managing hair loss.